Does RCA improve outcomes compared to UFH in critically ill patients requiring CRRT?
Regional citrate anticoagulation (RCA) is the preferred anticoagulant over unfractionated heparin for critically ill patients requiring continuous renal replacement therapy.
Compared to UFH, RCA is the preferred anticoagulant for critically ill patients requiring CRRT. The SUCRA analysis and forest plot of Regional-UFH + PGI2 are limited, as only a single study was included. Additional high-quality studies are necessary before any recommendation of Regional-UFH + PGI2. Further larger high-quality RCTs are desirable to strengthen the evidence on the best choice of anticoagulation options to reduce all-cause mortality and adverse events and promote the recovery of kidney function. Trial registration The protocol of this network meta-analysis was registered on PROSPERO ( CRD42022360263 ). Registered 26 September 2022.
Zhou et al. (Wed,) studied this question.